

pharmaceutically acceptable salts of such compounds where possible; or at least one further antidiabetic phenylacetic acid derivative or a pharmaceutically acceptable salt thereof.

7. (Amended) Combination according to claim 1, characterized in that nateglinide is present in the B-type or H-type crystal modification.

8. (Amended) Method of improving the bodily appearance of a mammal which comprises orally administering to said mammal a combination according to claim 1 in a dosage effective to influence the glucose metabolism, and repeating said dosage until a cosmetically beneficial loss of body weight has occurred.

10. (Amended) A pharmaceutical composition comprising a quantity, which is jointly therapeutically effective against metabolic disorders, of a combination according to claim 1, and at least one pharmaceutically acceptable carrier.

11. (Amended) Use of a combination according to claim 1 for the preparation of a medicament for the prevention, delay of progression or treatment of metabolic disorders.

12. (Amended) Use of a combination according to claim 1 for the cosmetic treatment of a mammal in order to effect a cosmetically beneficial loss of body weight.

Please add the following claims:

14. Combination according to claim 2, wherein the combination comprises the antidiabetic phenylacetic acid derivative repaglinide or a pharmaceutically acceptable salt thereof.

15. Combination according to claim 2, characterized in that the combination comprises acarbose.

16. Combination according to claim 2, characterized in that the combination comprises at least one further pharmaceutically active compound selected from the group consisting of antidiabetic thiazolidinediones, sulphonyl urea derivatives, metformin, and insulin, or the pharmaceutically acceptable salts of such compounds where possible; or at least one further antidiabetic phenylacetic acid derivative or a pharmaceutically acceptable salt thereof.